LAG-3 Antibody Relatlimab Combined With PD-1 Inhibition Improves PFS in Previously Untreated Melanoma

Source: cancernetwork, March 2021

The randomized, double-blind phase 2/3 RELATIVITY-047 trial (NCT03470922) examining the experimental anti–LAG-3 antibody relatlimab plus nivolumab (Opdivo) versus nivolumab alone in patients with treatment-naïve metastatic or unresectable melanoma met its primary end point of progression-free survival, according to Bristol Myers Squibb who is responsible for developing the agent.1

The fixed-dose combination regimen of the trial’s experimental arm was well tolerated with no new apparent safety signals for either arm. Follow-up for the secondary end point of overall survival remains ongoing.

READ THE ORIGINAL FULL ARTICLE